MK-8189

Experimental drug

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-2-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]-N-[(1S)-1-(4-fluorophenyl)ethyl]propanamide | image = MK-8189.svg | image2 = | width = 200 | alt = | caption = Chemical structure of MK-8189 | tradename = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 123456-78-9 | ATC_prefix = | ATC_suffix = | PubChem = 12345678 | DrugBank = | ChemSpiderID = 12345678 | UNII = | KEGG = | ChEBI = | ChEMBL = | synonyms = }}

MK-8189 is an investigational drug developed by Merck & Co. for the treatment of schizophrenia and other psychiatric disorders. It is a small molecule that acts as a phosphodiesterase 10A (PDE10A) inhibitor, which is a novel mechanism of action for antipsychotic therapy.

Mechanism of Action

MK-8189 functions by inhibiting the enzyme phosphodiesterase 10A (PDE10A), which is predominantly expressed in the striatum of the brain. PDE10A is involved in the regulation of intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which are important secondary messengers in neuronal signaling. By inhibiting PDE10A, MK-8189 increases the levels of cAMP and cGMP, leading to enhanced signaling pathways that are believed to be beneficial in treating symptoms of schizophrenia.

Clinical Development

MK-8189 has undergone various stages of clinical trials to evaluate its efficacy and safety in patients with schizophrenia. Early phase studies have shown promise in terms of improving both positive and negative symptoms of schizophrenia, with a favorable side effect profile compared to traditional antipsychotics.

Potential Benefits

The development of MK-8189 is significant because it represents a shift from traditional dopamine receptor antagonists, which are the mainstay of current antipsychotic treatments. By targeting PDE10A, MK-8189 offers a novel approach that may reduce the risk of side effects such as extrapyramidal symptoms and metabolic syndrome, which are commonly associated with dopamine receptor antagonists.

Challenges and Considerations

While MK-8189 shows potential, there are challenges in its development. The complexity of schizophrenia as a disorder means that a single-target approach may not be sufficient for all patients. Additionally, long-term safety and efficacy data are needed to fully understand the potential of MK-8189 as a treatment option.

Related Pages

• Schizophrenia
• Phosphodiesterase inhibitors
• Antipsychotic
• Merck & Co.